Neuromyelitis Optica: What You Need to Know Now and in the Future

Author(s)/Faculty: Patricia K. Coyle, MD, FAAN, FANA; Bruce A. C. Cree, MD, PhD, MAS, FAAN, FANA; Prem S. Subramanian, MD, PhD; Megan R. Weigel, DNP, ARNP-c, MSCN
Release Date: 12/27/2021Expiration Date: 12/26/2022
Credit Type: CME / CNENumber of Credits: 1.25
Content Type: LectureProvider:
Neuromyelitis optica spectrum disorder (NMOSD) is a rare, relapsing, autoimmune disease of the central nervous system, mainly manifesting through recurrent attacks of optic neuritis and longitudinally extensive transverse myelitis. Diagnosing NMOSD is challenging, but diagnostic criteria—based on the presence of core clinical characteristics, aquaporin-4 antibody status, and magnetic resonance imaging—have been developed that allow for a differential diagnosis from other inflammatory disorders of the central nervous system. Early stages are frequently misdiagnosed as multiple sclerosis. In addition, treatment options for NMOSD have been historically limited, until recently—when the US Food and Drug Administration approved several novel therapies for the treatment and prevention of NMOSD attacks. Additional therapies are currently under clinical review for the same indication. These approved and emerging therapies are changing the treatment paradigm for NMOSD, providing enhanced clinical outcomes for these patients with the goal of reducing relapse through early intervention. In this educational program, experts in the field present didactic information and cases, as well as engage in a panel discussion, to summarize evidence-based diagnostic criteria and best practices that assist in the differential diagnosis of NMOSD, as well as differentiate current NMOSD therapeutics based on their mechanisms of action, efficacy, safety, and administration. This program also examines interdisciplinary best practices that can assist in the acute and long-term care of patients with NMOSD.